Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in J Infect

Retrieve available abstracts of 164 articles:
HTML format

Single Articles

    July 2024
  1. WANG B, Mohammed H, Andraweera P, McMillan M, et al
    Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
    J Infect. 2024 Jul 8:106225. doi: 10.1016/j.jinf.2024.106225.
    PubMed     Abstract available

    June 2024
  2. DU Z, Wang S, Chen R, Shan S, et al
    Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults.
    J Infect. 2024;89:106211.

  3. GONG X, Peng L, Wang F, Liu J, et al
    Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    J Infect. 2024;89:106208.
    PubMed     Abstract available

  4. ZHAI K, Dong J, Zeng J, Cheng P, et al
    Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic Avian Influenza A(H9N2) Viruses.
    J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199.
    PubMed     Abstract available

  5. AUDRAN R, Karoui O, Donnet L, Soumas V, et al
    Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    J Infect. 2024 Jun 17:106205. doi: 10.1016/j.jinf.2024.106205.
    PubMed     Abstract available

  6. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    J Infect. 2024;88:106165.

  7. TSANG RSW, Deceuninck G, Meilleur C, Zhou J, et al
    Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex.
    J Infect. 2024;88:106163.
    PubMed     Abstract available

    May 2024
  8. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
    J Infect. 2024;89:106187.
    PubMed     Abstract available

  9. AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al
    Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
    J Infect. 2024;89:106179.

  10. PANG CWK, Vale R, Lao KS, Khan AT, et al
    Increased Incidence of Invasive Pneumococcal Disease in Hong Kong in 2023.
    J Infect. 2024 May 11:106178. doi: 10.1016/j.jinf.2024.106178.
    PubMed     Abstract available

  11. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    PubMed     Abstract available

    April 2024
  12. MENGYANG G, Yahong H, Qinghong M, Wei S, et al
    Resurgence and atypical patterns of pertussis in China.
    J Infect. 2024;88:106140.

    March 2024
  13. NG M, S D, L W, R B, et al
    Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.
    J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
    PubMed     Abstract available

  14. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.

  15. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.

  16. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    PubMed     Abstract available

  17. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    PubMed     Abstract available

    February 2024
  18. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    PubMed     Abstract available

  19. KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
    Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccines.
    J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.

  20. AL-ABRI SS, Abuhasan MY, Albayat SSA, Bai X, et al
    Meningococcal disease in the Middle East: A report from the Global Meningococcal Initiative.
    J Infect. 2024;88:71-76.
    PubMed     Abstract available

    January 2024
  21. HARRISON T, Clark J, Darton TC
    Less is more: uptake of recommended vaccines in a UK Travel Clinic.
    J Infect. 2024 Jan 25:S0163-4453(24)00027-6. doi: 10.1016/j.jinf.2024.

    November 2023
  22. DIEP AN, Schyns J, Gourzones C, Goffin E, et al
    How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: an 18-month longitudinal study.
    J Infect. 2023 Nov 17:S0163-4453(23)00558-3. doi: 10.1016/j.jinf.2023.

  23. BRENDISH NJ, Davis C, Chapman ME, Borca F, et al
    Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
    J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  24. LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al
    Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis - A prospective, nationwide cohort study from the Netherlands.
    J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023.

  25. HALL VJ, Insalata F, Foulkes S, Kirwan P, et al
    Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  26. LUNT R, Quinot C, Kirsebom F, Andrews N, et al
    The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
    J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

    October 2023
  27. JIN Z, Wu J, Wang Y, Huang T, et al
    Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
    J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  28. HA L, Levian C, Greene N, Goldfarb I, et al
    Association between acceptance of routine pregnancy vaccinations and COVID-19 vaccine uptake in pregnant patients.
    J Infect. 2023 Oct 19:S0163-4453(23)00541-8. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

    September 2023
  29. ANTONELLI M, Penfold RS, Canas LDS, Sudre C, et al
    SARS-CoV-2 infection following booster vaccination: illness and symptom profile in a prospective, observational community-based case-control study.
    J Infect. 2023 Sep 28:S0163-4453(23)00461-9. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  30. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection against Delta infection after vaccination: a nested case-control within the UK-based SIREN study.
    J Infect. 2023 Sep 7:S0163-4453(23)00380-8. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  31. PARRY H, Bruton R, Uwenedi G, Roberts T, et al
    Robust generation of neutralising antibodies against omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years.
    J Infect. 2023 Sep 1:S0163-4453(23)00499-1. doi: 10.1016/j.jinf.2023.

  32. AMANO M, Ichikawa Y, Matsumoto S, Matsushita S, et al
    Longitudinal analysis of neutralization in sera from HCWs receiving 2 doses of Omicron BA.4/5-adapted bivalent vaccine.
    J Infect. 2023 Sep 1:S0163-4453(23)00464-4. doi: 10.1016/j.jinf.2023.

    August 2023
  33. WHITAKER HJ, Tsang RS, Byford R, Aspden C, et al
    COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study.
    J Infect. 2023 Aug 12:S0163-4453(23)00456-5. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  34. WAGENHAUSER I, Mees J, Reusch J, Lam TT, et al
    Determinants of Influenza A Infection Rate in Post-COVID-19 Era.
    J Infect. 2023 Aug 9:S0163-4453(23)00455-3. doi: 10.1016/j.jinf.2023.

  35. FAUSTINI SE, Cook A, Hill H, Al-Taei S, et al
    Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
    J Infect. 2023 Aug 3:S0163-4453(23)00439-5. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

    July 2023
  36. BENN CS, Aaby P
    Measles vaccination and reduced child mortality: Prevention of immune amnesia or beneficial non-specific effects of measles vaccine?
    J Infect. 2023 Jul 21:S0163-4453(23)00382-1. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  37. KAMBOJ M, Laracy JC, Usiak S, Babady NE, et al
    Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
    J Infect. 2023 Jul 13:S0163-4453(23)00378-X. doi: 10.1016/j.jinf.2023.

  38. BAYHAN GI, Guner R, Yahsi A, Ozkul A, et al
    Evaluation of the neutralizing antibody response against the omicron variant produced by heterologous or hybrid immunity: How does the fifth dose of COVID-19 vaccine affect the neutralizing antibody response?
    J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023.

  39. TAUCHER C, Lazarus R, Dellago H, Maurer G, et al
    Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COM
    J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

    June 2023
  40. VARASI I, Lai A, Fiaschi L, Bergna A, et al
    Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination.
    J Infect. 2023 Jun 30:S0163-4453(23)00342-0. doi: 10.1016/j.jinf.2023.

  41. KELLY E, Greenland M, de Whalley PCS, Aley PK, et al
    Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.
    J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  42. FALLET B, Foglierini M, Porret R, Alcaraz A, et al
    Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
    J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  43. HIGHAM SL, Baker S, Flight KE, Krishna A, et al
    Intranasal immunization with outer membrane vesicles (OMV) protects against airway colonization and systemic infection with Acinetobacter baumannii.
    J Infect. 2023;86:563-573.
    PubMed     Abstract available

    May 2023
  44. WANG B, Giles L, Andraweera P, McMillan M, et al
    4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post program implementation.
    J Infect. 2023 May 31:S0163-4453(23)00300-6. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  45. NG RW, Sze RK, Chong KC, Zhao S, et al
    Effectiveness of mRNA and inactivated COVID-19 vaccines: a test-negative study in an infection-naive Hong Kong population.
    J Infect. 2023 May 26:S0163-4453(23)00298-0. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  46. KANG SW, Kim JY, Park H, Lim SY, et al
    Corrigendum to "Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection" [J Infect 85 (2022) e69-e71].
    J Infect. 2023 May 25:S0163-4453(23)00294-3. doi: 10.1016/j.jinf.2023.

  47. FAVRESSE J, Cabo J, Douxfils J
    Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection.
    J Infect. 2023 May 19:S0163-4453(23)00292-X. doi: 10.1016/j.jinf.2023.

    April 2023
  48. LIU X, Munro APS, Wright A, Feng S, et al
    Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    J Infect. 2023 Apr 19:S0163-4453(23)00247-5. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  49. LIU X, Munro AP, Feng S, Janani L, et al
    Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
    J Infect. 2023 Apr 11:S0163-4453(23)00198-6. doi: 10.1016/j.jinf.2023.

  50. SHAW RH, Greenland M, Stuart AS, Aley PK, et al
    Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    J Infect. 2023 Apr 5:S0163-4453(23)00199-8. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

  51. NYGREN TM, Pilic A, Bohmer MM, Wagner-Wiening C, et al
    Tick-borne encephalitis: Acute clinical manifestations and severity in 581 cases from Germany, 2018-2020.
    J Infect. 2023;86:369-375.
    PubMed     Abstract available

    March 2023
  52. BHAT S, Das L, Maheshwari D, Badal D, et al
    Effect of Calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial.
    J Infect. 2023 Mar 6:S0163-4453(23)00131-7. doi: 10.1016/j.jinf.2023.

    February 2023
  53. SHAVA E, Izu A, Gaolathe T, Walker A, et al
    Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.
    J Infect. 2023 Feb 28:S0163-4453(23)00123-8. doi: 10.1016/j.jinf.2023.

  54. ZHOU P, Gong F, Ji T, Cao C, et al
    Enriched CXCR3(+) CXCR5(+) CD8(+) T cells in SARS-CoV-2 infected and vaccinated individuals effectively respond to the antigen in recall.
    J Infect. 2023 Feb 23:S0163-4453(23)00109-3. doi: 10.1016/j.jinf.2023.

  55. VALENTINI D, Carfi A, Di Paola A, Yarci-Carrion A, et al
    Factor associated with SARS-CoV-2 vaccination serological efficacy in adolescents and adults with Down syndrome: data from an international, collaborative initiative of the Trisomy 21 Research SocietyRUNNING TITLE: Factors determining COVID-19 vaccine
    J Infect. 2023 Feb 20:S0163-4453(23)00090-7. doi: 10.1016/j.jinf.2023.

  56. EVANS A, Qi C, Adebayo JO, Underwood J, et al
    Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.
    J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available

    January 2023
  57. AMANO M, Ichikawa Y, Uemura Y, Matsumoto S, et al
    Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.
    J Infect. 2023 Jan 31:S0163-4453(23)00066-X. doi: 10.1016/j.jinf.2023.

  58. RANA MS, Usman M, Alam MM, Tahir M, et al
    The emergence of Mumps after the COVID-19 Pandemic in Pakistan: time to consider MMR vaccination strategies.
    J Infect. 2023 Jan 26:S0163-4453(23)00057-9. doi: 10.1016/j.jinf.2023.

  59. NISAR MI, Ansari N, Malik AA, Shahid S, et al
    Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative case-control study.
    J Infect. 2023 Jan 25:S0163-4453(23)00021-X. doi: 10.1016/j.jinf.2023.

  60. ZHAN H, Yang L, Liu Y, Li H, et al
    Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
    J Infect. 2023 Jan 21:S0163-4453(23)00034-8. doi: 10.1016/j.jinf.2023.

  61. XU J, Wang Y, Duan G, Liu F, et al
    Impact of non-pharmaceutical interventions during COVID-19 pandemic on measles and mumps in mainland China.
    J Infect. 2023 Jan 9:S0163-4453(23)00008-7. doi: 10.1016/j.jinf.2023.

  62. CHOUCHANA L, Fournier D, Lebrun-Vignes B, Florence S, et al
    Facial Nerve Palsy As A Possible Adverse Drug Reaction Of The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Smallpox Vaccine: a pharmacovigilance analysis.
    J Infect. 2023 Jan 8:S0163-4453(23)00006-3. doi: 10.1016/j.jinf.2023.

  63. LI Y, Liang H, Ding X, Cao Y, et al
    Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: A systematic review and meta-analysis.
    J Infect. 2023 Jan 6:S0163-4453(23)00001-4. doi: 10.1016/j.jinf.2023.

  64. CAMACHO J, Zulaica J, Gimenez E, Rusu L, et al
    Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naive individuals in the general population.
    J Infect. 2023 Jan 1:S0163-4453(22)00755-1. doi: 10.1016/j.jinf.2022.

    December 2022
  65. SCHILDGEN O, Lusebrink J, Schildgen V
    Recommendation for broad use of Covid-19 mRNA vaccine boosters due to waning vaccine effectiveness is taking the easy way out.
    J Infect. 2022 Dec 24:S0163-4453(22)00744-7. doi: 10.1016/j.jinf.2022.

  66. LI X, Peng K, Cheng FW, Lam DC, et al
    Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
    J Infect. 2022 Dec 17:S0163-4453(22)00706-X. doi: 10.1016/j.jinf.2022.

  67. HANNAWI S, Safeldin L, Abuquta A, Alamadi A, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Protein Booster Vaccine, SCTV01C in Adults Previously Vaccinated with Inactivated Vaccine: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Trial.
    J Infect. 2022 Dec 9:S0163-4453(22)00693-4. doi: 10.1016/j.jinf.2022.

  68. POZO-BALADO MDM, Ramos A, Rodriguez VG, Martinez IO, et al
    J Infect. 2022 Dec 8:S0163-4453(22)00692-2. doi: 10.1016/j.jinf.2022.

  69. RACCAGNI AR, Candela C, Mileto D, Bruzzesi E, et al
    Breakthrough Monkeypox Infection among Individuals Previously Immunized with Smallpox or Monkeypox Vaccination.
    J Infect. 2022 Dec 5:S0163-4453(22)00690-9. doi: 10.1016/j.jinf.2022.

    November 2022
  70. CHEN D, Pan Y, Wang Y, Chen X, et al
    Serological response to COVID-19 vaccine and its predictors in patients with solid malignancies: a systematic review and meta-analysis of 16 cohort studies.
    J Infect. 2022 Nov 26:S0163-4453(22)00673-9. doi: 10.1016/j.jinf.2022.

  71. ZHAO Y, Zhao Y, Zhou Y, Zhang Z, et al
    Inactivated COVID-19 vaccination and maternal renal function during early pregnancy: a retrospective cohort study of 6397 Chinese pregnant women.
    J Infect. 2022 Nov 22:S0163-4453(22)00676-4. doi: 10.1016/j.jinf.2022.

  72. YARCI-CARRION A, Esparcia-Pinedo L, Mateo-Jimenez G, Alfranca A, et al
    Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with Down syndrome.
    J Infect. 2022 Nov 20:S0163-4453(22)00675-2. doi: 10.1016/j.jinf.2022.

  73. WANG X, Sima L
    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    J Infect. 2022 Nov 20:S0163-4453(22)00674-0. doi: 10.1016/j.jinf.2022.
    PubMed     Abstract available

  74. WANG G, Zhao K, Han J, Hu Z, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Recombinant Protein Vaccine, SCTV01C in Unvaccinated Adults: A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial.
    J Infect. 2022 Nov 17:S0163-4453(22)00649-1. doi: 10.1016/j.jinf.2022.

  75. MILLER P, Patel SR, Skinner R, Dignan F, et al
    Joint Consensus Statement on the Vaccination of Adult and Paediatric Haematopoietic Stem Cell Transplant Recipients. Prepared on Behalf of the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), the Children's Cancer an
    J Infect. 2022 Nov 15. pii: S0163-4453(22)00646.
    PubMed     Abstract available

  76. MASHIMO Y, Yamazaki K, Kageyama T, Tanaka S, et al
    Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine.
    J Infect. 2022 Nov 2. pii: S0163-4453(22)00614.

    October 2022
  77. HE WQ, Gianacas C, Muscatello DJ, Newall AT, et al
    Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study.
    J Infect. 2022 Oct 23. pii: S0163-4453(22)00626.
    PubMed     Abstract available

  78. KANDEL C, Lee Y, Taylor M, Llanes A, et al
    Viral Dynamics of the SARS-CoV-2 Omicron Variant Among Household Contacts with 2 or 3 COVID-19 Vaccine Doses.
    J Infect. 2022 Oct 22. pii: S0163-4453(22)00625.
    PubMed     Abstract available

  79. NISHIKIMI A, Nakagawa T, Fujiwara M, Watanabe K, et al
    Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00621.

  80. ASTURIAS EJ, Bai X, Bettinger JA, Borrow R, et al
    Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00623.
    PubMed     Abstract available

  81. ZHOU J, Zhao P, Nie M, Gao K, et al
    Changes of Haemophilus influenzae infection in children before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00615.

  82. ZHENG Q, Wang M, Cheng Y, Liu J, et al
    Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients.
    J Infect. 2022 Oct 17. pii: S0163-4453(22)00612.

  83. NAZARETH J, Barr I, Sullivan SG, Goss C, et al
    Intra-season waning of immunity following the seasonal influenza vaccine in early and late vaccine recipients.
    J Infect. 2022 Oct 13. pii: S0163-4453(22)00604.

  84. LEE J, Park S, Kim JY, Lim SY, et al
    No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
    J Infect. 2022 Oct 9. pii: S0163-4453(22)00600.

    September 2022
  85. HUANG J, Xia L, Zhao Y, Wu X, et al
    Coronavirus disease 2019 vaccination and live birth outcome after fresh embryo transfer.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00552.

  86. AO G, Li A, Wang Y, Tran C, et al
    The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: a meta-analysis.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00553.

  87. YIN Y, Lin J, Yuan S, Tong S, et al
    A booster shot of vaccine against SARS-CoV-2 should be rigorously promoted and implemented in China.
    J Infect. 2022 Sep 25. pii: S0163-4453(22)00546.

  88. XU QY, Zheng XQ, Jia ZJ, Wu MJ, et al
    Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study.
    J Infect. 2022 Sep 12. pii: S0163-4453(22)00539.

  89. MOUSSAOUI ME, Desmecht S, Tashkeev A, Lambert N, et al
    Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naive people living with HIV.
    J Infect. 2022 Sep 9. pii: S0163-4453(22)00534.

  90. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study.
    J Infect. 2022 Sep 8. pii: S0163-4453(22)00535.
    PubMed     Abstract available

  91. BEKKAT-BERKANI R, Fragapane E, Preiss S, Rappuoli R, et al
    Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    J Infect. 2022 Sep 7. pii: S0163-4453(22)00530.
    PubMed     Abstract available

  92. SHI T, Dai M, Liu F, Hu J, et al
    Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00521.

  93. DIMEGLIO C, Tremeaux P, Herin F, Da-Silva I, et al
    Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00522.

    August 2022
  94. GIDARI A, Schiaroli E, Sabbatini S, Bastianelli S, et al
    Impact of SARS-CoV-2 Omicron Variants on Serum Neutralization in a Cohort of Healthcare Workers Vaccinated with BNT162b2.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00507.

  95. LI K, Ruan F, Zhao Z, Guo Z, et al
    Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China.
    J Infect. 2022 Aug 22. pii: S0163-4453(22)00502.

  96. WAN EYF, Mok AHY, Yan VKC, Wang B, et al
    Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study.
    J Infect. 2022 Aug 16. pii: S0163-4453(22)00472.

    July 2022
  97. NOH JY, Cheong HJ, Kim WJ, Choi JY, et al
    Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination: Running title: Optimal vaccination interval and ceiling effect.
    J Infect. 2022 Jul 31. pii: S0163-4453(22)00456.

  98. HAGIYA H, Hikita T, Habu T, Asada M, et al
    Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people.
    J Infect. 2022 Jul 11. pii: S0163-4453(22)00413.

  99. YAN Y, Davgadorj C, Lyu C, Zhang S, et al
    Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00407.

    June 2022
  100. XIAO J, Zhu Q, Yang F, Zeng S, et al
    The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China:a longitudinal surveillance study.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00376.
    PubMed     Abstract available

  101. YIN Y, Li X, Qian C, Cheng B, et al
    Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00374.

  102. NIYOMNAITHAM S, Toh ZQ, Licciardi PV, Wongprompitak P, et al
    Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00370.

  103. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    PubMed     Abstract available

  104. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.

  105. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.

  106. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.

  107. CHEN CH, Janapatla RP, Su LH, Li HC, et al
    Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.
    J Infect. 2022;84:788-794.
    PubMed     Abstract available

  108. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak.
    J Infect. 2022;84:e95-e97.

    May 2022
  109. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.

  110. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.

  111. VAN GRONINGEN KM, Dao BL, Gounder P
    Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county.
    J Infect. 2022 May 9. pii: S0163-4453(22)00259.

  112. DIMEGLIO C, Migueres M, Chapuy-Regaud S, Da-Silva I, et al
    Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response.
    J Infect. 2022 May 7. pii: S0163-4453(22)00258.

  113. MARSAY L, Dold C, Paterson GK, Yamaguchi Y, et al
    Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.
    J Infect. 2022;84:658-667.
    PubMed     Abstract available

    April 2022
  114. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    PubMed     Abstract available

  115. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Reduced neutralizing antibody response in naive Covishield vaccinees against Omicron emphasizes booster vaccination.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00213.

  116. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.

  117. LIU X, Munro APS, Feng S, Janani L, et al
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00200.
    PubMed     Abstract available

  118. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00197.

  119. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.

  120. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.

  121. CHENG CY, Hsiao SH, Fang TC, Lin YC, et al
    SARS-CoV2 Antibody Response After a Third Dose of Heterologous ChAdOx1 nCoV-19 and Moderna Vaccine in Chronic Dialysis Patients.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00190.

  122. LIN J, Dobbins T, Wood JG, Bernardo C, et al
    Impact of a national immunisation program on herpes zoster incidence in Australia.
    J Infect. 2022;84:537-541.
    PubMed     Abstract available

    March 2022
  123. SCHILDGEN V, Lusebrink J, Schildgen O
    Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnarable individuals.
    J Infect. 2022 Mar 23. pii: S0163-4453(22)00173.

  124. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees.
    J Infect. 2022 Mar 19. pii: S0163-4453(22)00170.

  125. DIMEGLIO C, Loubes JM, Migueres M, Saune K, et al
    Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants.
    J Infect. 2022 Mar 17. pii: S0163-4453(22)00140.

  126. XIANG B, Yang L, Ye Z, Ren T, et al
    Vaccination of Susceptible Animals Against SARS-CoV-2.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00131.

  127. FERRE VM, Lebourgeois S, Chenane HR, Menidjel R, et al
    Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00126.

  128. BONNET B, Chabrolles H, Archimbaud C, Brebion A, et al
    Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00132.

  129. GIMENEZ E, Albert E, Burgos JS, Peiro S, et al
    SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00124.
    PubMed     Abstract available

  130. BONGIOVANNI M, Spada E, De Angelis C, Liuzzi G, et al
    SARS-CoV-2: about reinfection, vaccination and neutralizing antibodies.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00125.

  131. SYED MA DR, A/Qotba HA Dr, Al Nuaimi AS Dr
    Effectiveness of COVID-19 vaccines in Qatar.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00121.

  132. SCHALTZ-BUCHHOLZER F, Bjerregard Oland C, Berendsen M, Bjerregaard-Andersen M, et al
    Maternal BCG primes for enhanced health benefits in the newborn.
    J Infect. 2022;84:321-328.
    PubMed     Abstract available

  133. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.

    February 2022
  134. PUTRI DU, Lin CF, Hung CS, Huang CK, et al
    Distinct B and NKT cell Responses Shape the Delayed Response to ChAdOx1 nCoV-19 Vaccine in End-Stage Renal Disease.
    J Infect. 2022 Feb 28. pii: S0163-4453(22)00116.

  135. HAYASHI JY, Simizo A, Miyamoto JG, Costa LVS, et al
    Humoral and Cellular Responses to Vaccination with Homologous CoronaVac or ChAdOx1 and Heterologous Third Dose with BNT162b2.
    J Infect. 2022 Feb 27. pii: S0163-4453(22)00115.

  136. TANG K, Wu X, Luo Y, Wei Z, et al
    Meta-analysis of Immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00081.

  137. SAHAY RR, Patil DY, Sapkal GN, Deshpande GR, et al
    SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00082.

  138. FERRI S, Polidoro A, Ciacciarelli M, Ceratti U, et al
    Decline of immune humoral response after BNT162b2 Vaccine.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00076.

  139. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected.
    J Infect. 2022 Feb 15. pii: S0163-4453(22)00073.

  140. LIU F, Wang H, Cao Y, Zhang N, et al
    Effectiveness of varicella vaccine in 1-year-old children: a matched case-control study.
    J Infect. 2022 Feb 11. pii: S0163-4453(22)00069.

  141. WESTROP SJ, Whitaker HJ, Powell AA, Power L, et al
    Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
    J Infect. 2022 Feb 4. pii: S0163-4453(22)00055.
    PubMed     Abstract available

  142. ESTOFOLETE CF, Fares GF, Banho CA, Sacchetto L, et al
    Predictors of death in COVID-19 vaccine breakthrough infections in Brazil.
    J Infect. 2022 Feb 2. pii: S0163-4453(22)00059.

    January 2022
  143. XU W, Tang J, Chen C, Wang C, et al
    Safety and Efficacy of the Covid-19 Vaccine in children andor adolescents: A meta-analysis.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00050.

  144. MATTIUZZI C, Lippi G
    COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00051.

  145. MENSAH AA, Lacy J, Stowe J, Seghezzo G, et al
    Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study.
    J Infect. 2022 Jan 24. pii: S0163-4453(22)00010.
    PubMed     Abstract available

  146. DUCLOUX D, Bamoulid J, Chabannes M, Colladant M, et al
    Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00020.

  147. FAUSTINI S, Shields A, Banham G, Wall N, et al
    Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00002.

  148. YANG Y, Gong X, Yang L, Li J, et al
    Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00005.

  149. DE MICHELENA P, Torres I, Albert E, Bracho A, et al
    Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00007.

  150. WHITAKER HJ, Tsang RS, Byford R, Andrews NJ, et al
    Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups.
    J Infect. 2022 Jan 3. pii: S0163-4453(21)00664.
    PubMed     Abstract available

  151. MARRAMS ARM, Kobayashi T, Suzuki H, Alsuhaibani M, et al
    Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis.
    J Infect. 2022 Jan 1. pii: S0163-4453(21)00658.
    PubMed     Abstract available

    December 2021
  152. MIN JY, Mwakingwe-Omari A, Riley M, Molo LY, et al
    The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=50 Years: a Randomized Trial.
    J Infect. 2021 Dec 25. pii: S0163-4453(21)00651.
    PubMed     Abstract available

  153. COSTA R, Olea B, Bracho MA, Albert E, et al
    RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00641.

  154. MANOLACHE NG, Ursachi V, Scohy A, Desmet C, et al
    Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.
    J Infect. 2021 Dec 14. pii: S0163-4453(21)00597.

  155. MAK WA, Koeleman JGM, van der Vliet M, Keuren F, et al
    SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
    J Infect. 2021 Dec 9. pii: S0163-4453(21)00593.
    PubMed     Abstract available

    November 2021
  156. OESER C, Whitaker H, Linley E, Borrow R, et al
    Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.
    J Infect. 2021 Nov 30. pii: S0163-4453(21)00584.

  157. LUCIDARME J, Bai X, Lekshmi A, Clark SA, et al
    Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data: Meningococcal B following 4CMenB.
    J Infect. 2021 Nov 25. pii: S0163-4453(21)00579.
    PubMed     Abstract available

  158. ALDERSON MR, Arkwright PD, Bai X, Black S, et al
    Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.
    J Infect. 2021 Nov 24. pii: S0163-4453(21)00578.
    PubMed     Abstract available

  159. LEBOURGEOIS S, Menidjel R, Chenane HR, Ferre VM, et al
    Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00556.

  160. GIMENEZ E, Alberola J, Torres I, Albert E, et al
    Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2021 Nov 2. pii: S0163-4453(21)00542.

    October 2021
  161. CHONG Y, Tani N, Goto T, Yonekawa A, et al
    Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00508.

  162. GUPTA A, Bhoyar RC, Mirza S, Jolly B, et al
    SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.
    J Infect. 2021 Oct 19. pii: S0163-4453(21)00506.

  163. ANIS E, Haas EJ, Indenbaum V, Singer SR, et al
    A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19.
    J Infect. 2021 Oct 6. pii: S0163-4453(21)00497.
    PubMed     Abstract available

    September 2021
  164. FERRE VM, Lebourgeois S, Menidjel R, Collin G, et al
    Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00488.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.